Axitinib in metastatic renal cell carcinoma: patient characteristics and treatment patterns in US community oncology centers
| Autor: | Laura Cisar, Elizabeth A. MacLean, Xiaolong Jiao, Thomas E. Hutson, Thomas Wilson |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Indazoles Time Factors Axitinib medicine.drug_class Antineoplastic Agents Disease Medical Oncology Tyrosine-kinase inhibitor 03 medical and health sciences 0302 clinical medicine Renal cell carcinoma Internal medicine medicine Humans 030212 general & internal medicine Stage (cooking) Carcinoma Renal Cell Aged Retrospective Studies Aged 80 and over business.industry Imidazoles Cancer General Medicine Community Health Centers Middle Aged medicine.disease Kidney Neoplasms United States Treatment Outcome 030220 oncology & carcinogenesis Female business Kidney cancer Clear cell medicine.drug |
| Zdroj: | Future oncology (London, England). 13(15) |
| ISSN: | 1744-8301 |
| Popis: | Aim: To study patient characteristics and treatment patterns in real-world axitinib use for metastatic renal cell carcinoma. Patients & methods: We conducted a retrospective analysis of second- or third-line axitinib use between 1 January 2012 and 31 October 2014 in 135 metastatic renal cell carcinoma patients using the US Oncology Network database. Results: Overall, 86.7% had clear cell histology, 57.8% had stage III/IV disease at diagnosis and 55.6% were poor risk by Heng criteria. Median treatment duration was 4.6 months (range: 0.03–35.49); 80.7% initiated axitinib at 5 mg/day twice daily, and 67.4% maintained this dose. Overall, 77.8% discontinued treatment, mainly due to disease progression (50.5%) and toxicity (21.9%). Conclusion: Axitinib usage patterns were consistent with the National Comprehensive Cancer Network Guidelines®. Ease of use among community oncologists and patient tolerance are key features of axitinib. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|